For years, women have been warned that as many as 30% to 50% of breast cancers found on screening might never have caused them harm. A new analysis of all eight major randomized mammography trials says the real number of these “overdiagnosed” cancers may be under 5%.
The study, published September 14, 2026, in the Journal of the National Cancer Institute (JNCI), argues that much of the scary math behind mammogram overdiagnosis came from reading trial data too early. With Breast Cancer Awareness Month kicking off October 1, here’s what the new research found, why estimates have been all over the map, what critics say, and what current US screening guidance actually recommends.
What Is Mammogram Overdiagnosis?
Mammogram overdiagnosis happens when screening finds a real breast cancer that would never have caused symptoms or threatened a woman’s life. Without the mammogram, she would never have known it was there.
That’s different from a false positive. A false positive is a scare that turns out to be nothing. An overdiagnosed cancer is a genuine cancer under the microscope – it just would have stayed quiet, grown too slowly to matter, or been outpaced by other health problems.
According to the researchers’ fact sheet, the definition can also cover women who die of another cause shortly after a breast cancer diagnosis, when poor health or limited life expectancy meant treatment was unlikely to help.
The catch: no doctor can look at an individual tumor and say “this one is overdiagnosed.” As the U.S. Preventive Services Task Force (USPSTF) notes, overdiagnosis can only be estimated indirectly across large groups of screened people. That’s exactly why the numbers have been so hotly debated.
Inside the New JNCI Study
The meta-analysis was led by Sisse Helle Njor, a professor at the University of Southern Denmark and Lillebaelt Hospital, with co-authors Casper Urth Pedersen, Elsebeth Lynge (University of Copenhagen), Matejka Rebolj (Queen Mary University of London) and Robert A. Smith of the American Cancer Society.
The team pulled together all eight randomized mammography trials:
- New York Health Insurance Plan (HIP)
- Malmo (Sweden)
- Two-County (Sweden)
- Edinburgh
- Canadian National Breast Screening Study
- Stockholm
- Gothenburg
- UK Age
They then compared the trials with real-world data from Denmark, where organized screening started in some regions 17 years before others. That natural experiment let researchers watch how diagnoses changed right after screening began – and how the pattern evolved over the long run. Both invasive cancer and ductal carcinoma in situ (DCIS) were included.
The headline finding: the extra breast cancer cases in the trials closely matched what would be expected in the Danish screening population, where overdiagnosis is estimated to be below 5%, according to the University of Southern Denmark’s news release.
“Randomized trials have often been cited as evidence that overdiagnosis is a substantial problem. Our study shows that this interpretation is not as straightforward as it may seem,” Njor said in the release.
Why Mammogram Overdiagnosis Estimates Varied So Much
Here’s the key idea, and it’s surprisingly intuitive. When screening starts, diagnoses jump – because mammograms catch cancers earlier than they would otherwise be found. Later, diagnoses should dip, because some of those cancers were simply “pulled forward” in time.
If you stop counting before that dip shows up, the early bump looks like a pile of extra cancers that never needed finding. That’s the “noise” the study title refers to.
The researchers focused on three factors that can inflate overdiagnosis estimates:
- Control groups got screened too. Women in many trials’ “no screening” groups were screened after the trial ended or once national programs launched. That muddies the comparison.
- Different numbers of screening rounds. More rounds mean more chances to find cancers early.
- Follow-up length. Longer follow-up gives time for early-found cancers to “show up” in the control group, too.
“If researchers do not take these factors into account, the initial increase can be mistaken for overdiagnosis,” said Lynge, professor emerita at the University of Copenhagen.
Rebolj put it more bluntly: “When interpreted in their full temporal context, randomized trial data are consistent with overdiagnosis of less than five percent, rather than with estimates nearing 50%.”
The Critics’ Case: Real Caveats
Not everyone thinks this settles the debate. Kefah Mokbel, chair of breast cancer surgery at the London Breast Institute, called the work important but raised three caveats in a LinkedIn post republished by the oncology news site OncoDaily:
- It’s a compatibility check, not a precise number. The study shows trial data fit a low-overdiagnosis pattern; it doesn’t produce a single pooled estimate with a confidence interval. “Agreement with an expected pattern is weaker evidence than a confidence interval around a number,” Mokbel wrote.
- Everything rides on Denmark. The Danish reference (from Funen) is treated as the right comparison. Pick a different reference population and the answer could shift.
- Old technology. The trials used film mammography decades ago. They say little about how often today’s 3D mammography (tomosynthesis) finds DCIS – the early, non-invasive lesions most often tied to overdiagnosis concerns.
Mokbel also noted that a major UK Independent Panel review put overdiagnosis at roughly 19% of cancers diagnosed during the screening period in invited women – a figure that shaped many decision aids women receive today.
It’s also worth knowing that one co-author works for the American Cancer Society, a long-time screening advocate. That doesn’t make the analysis wrong, but independent replication will matter.
For balance, even the USPSTF’s own 2024 evidence review lands between the extremes. It says trials with good design and no screening of the control group at the end produced overdiagnosis estimates of roughly 11% to 19%, and modeling suggests about 14 overdiagnosed cancers per 1,000 women screened every other year from 40 to 74 (with a wide range of 4 to 37 across models).
What Current US Screening Guidelines Say
The new analysis doesn’t change any official guidance – yet. Here’s where things stand as of September 2026:
| Group | Recommendation for average-risk women |
|---|---|
| USPSTF (final, April 2024) | Mammogram every 2 years from age 40 through 74 (Grade B). Evidence insufficient for 75+. |
| American Cancer Society | Option to start yearly at 40-44; yearly at 45-54; every 1-2 years at 55+, continuing while in good health with 10+ years of life expectancy. |
The USPSTF recommendation lowered the starting age from 50 to 40 in 2024. The task force also flagged dense breasts: nearly half of women have them, which raises cancer risk and can make mammograms less effective. It said evidence is still insufficient to judge extra ultrasound or MRI screening for women with dense breasts and an otherwise normal mammogram.
These guidelines are for people at average risk. If you have a strong family history, a known genetic mutation like BRCA1 or BRCA2, or past chest radiation, your plan may look very different.
What Mammogram Overdiagnosis Findings Mean for You
If you’ve skipped screening because you worried about being treated for a cancer that “didn’t matter,” this study is worth a conversation with your doctor. It suggests that risk may be smaller than you were told – though experts still disagree on the exact size.
“Most women will not develop breast cancer, but with this study we can now be reassured that the benefits of detecting breast cancer early and preventing premature death will outweigh the small risk of unnecessary treatment,” Njor said.
At the same time, overdiagnosis isn’t the only trade-off. Mammograms also bring false positives, extra imaging and biopsies, and a small amount of radiation. Mokbel’s framing is a useful gut-check: “overstating overdiagnosis deters attendance, understating it erodes informed consent.”
Keep in mind, too, that this is a reanalysis of existing trials. It shows the old data are consistent with low overdiagnosis; it doesn’t directly prove the rate for any one woman or any one clinic. Want more context on reading health headlines? Our breakdown of a recent GLP-1 and breast cancer risk study walks through why “linked to” isn’t the same as “caused by.”
Your Breast Cancer Awareness Month Action Plan
October is the perfect nudge to get your screening sorted. Here’s a simple checklist:
- Check your age and last mammogram date. If you’re 40-74 and it’s been more than two years, it’s time to ask.
- Know your family history. Write down any relatives with breast, ovarian, prostate or pancreatic cancer, and their ages at diagnosis.
- Ask about breast density. Your mammogram report may say whether you have dense breasts. Ask what that means for you.
- Talk to your doctor about the trade-offs. Bring up overdiagnosis, false positives, and whether yearly or every-other-year screening fits your risk.
- Don’t ignore symptoms. A new lump, skin dimpling, nipple changes or discharge needs a doctor visit, no matter when your last mammogram was.
- Stack the boring basics. Regular activity, limiting alcohol and staying on top of checkups are the kind of habits our look at what 63 longevity experts actually rank highest keeps coming back to.
The bottom line: the new JNCI study suggests mammogram overdiagnosis may be a much smaller downside than many women were told, but it’s one analysis with real limits. Screening decisions are personal, so use this month to talk to your doctor about what makes sense for your age, history and risk.
This article is for general information and isn’t medical advice. Talk to your doctor or a qualified health professional about your own screening plan.
